Mixed Signals for AMN Healthcare as Earnings Beat Meets Institutional Exodus

AMN Healthcare Services delivered a positive earnings surprise that contrasted sharply with concerning revenue trends and a notable pullback by major institutional investors. The healthcare staffing specialist finds itself navigating declining sales and a gloomy forecast, yet some market analysts maintain a cautiously optimistic outlook on the company’s prospects.

Revenue Declines Overshadow Profit Performance

The company’s second-quarter financial results presented a complex picture. While AMN Healthcare’s adjusted earnings per share of $0.30 significantly exceeded analyst expectations of $0.19, the company experienced a substantial 11.1% drop in total revenue, which fell to $658.2 million. The outlook appears even more challenging, with management projecting a further 9-11% revenue decline for the current quarter.

Compounding these revenue challenges, AMN Healthcare recently completed the sale of its Smart Square software division to symplr for $75 million. This transaction is expected to reduce annual revenue by approximately $17 million, creating additional pressure on the company’s already weakened top-line performance.

Major Investor Reduces Stake Significantly

Institutional investment activity revealed divergent perspectives on AMN Healthcare’s future. Invesco Ltd. executed a substantial reduction of its position during the first quarter of 2025, decreasing its holdings by 40,043 shares—a notable 10.3% cut. This move leaves the major investor with just 0.91% of the company in its portfolio.

Should investors sell immediately? Or is it worth buying AMN Healthcare Services?

Other asset managers demonstrated a more measured approach. Both Cresset Asset Management and MetLife Investment Management made only marginal adjustments to their positions, indicating less pessimistic views compared to Invesco’s significant divestment.

Analyst Sentiment Remains Guardedly Positive

Despite the concerning revenue trajectory, some research firms maintain a constructive view on AMN Healthcare’s long-term potential. BMO Capital Markets, while reducing its price target from $27 to $22, sustained its “Outperform” rating on the company’s shares. This suggests that analysts perceive greater value in the stock than its current market price reflects.

The central question facing investors is whether the company’s demonstrated cost efficiency and earnings outperformance can sufficiently counterbalance persistent revenue concerns. Alternatively, the substantial institutional selling might signal deeper fundamental challenges within the healthcare staffing market that extend beyond AMN Healthcare’s immediate financial metrics.